JP Medical Consulting Pty Ltd (ACN 673 260 056, JP Medical) is pleased to announce the appointment of Mr. Neil Finlayson as Chief Operating Officer (COO).

Mr. Neil Finlayson brings with him over 30 years of extensive experience in drug development, clinical development, project management, and commercialization. He has served as CEO of several vaccine companies founded and led by Professor Ian Frazer, co-inventor of the world’s first cervical cancer vaccine.

Dr. James Pang, Founder and Chief Executive Officer of JP Medical, commented: “Neil and I have a long-standing professional relationship, having worked together within Professor Ian Frazer’s distinguished team. His outstanding capabilities, leadership, and track record are well-recognized across the industry. Neil’s addition will bring tremendous value to JP Medical and strongly support our continued growth as a fast-growing service platform dedicated to supporting Chinese companies conducting clinical trials in Australia.”

JP Medical is an Australian-registered Research Consulting Organisation (RCO). Utilizing a unique, integrated RCO-CRO business model, JP Medical has emerged as a rapidly growing Australian clinical service platform that operates through a group of independent companies working in collaboration. It provides full-suite solutions—including ethics submissions, TGA CTN/CTX, clinical trial operation, regulatory support, medical and clinical affairs, R&D rebates, and local sponsor services—for both Chinese pharmaceutical and biotech, and also for medical device companies in Australia to conduct clinical development in China.

With Mr. Neil Finlayson joining the leadership team, JP Medical will further enhance its operational strength and service capabilities to better serve its clients.